Geoffrey Straub Martha
Summary
Geoffrey Straub Martha has served as Medtronic’s CEO since April 2020 and as chairman since December 2020.
Biography
Martha joined Medtronic in 2011 and has held senior roles in strategy, business development, integration, and the Restorative Therapies Group. Before becoming CEO, he served as executive vice president and president of Restorative Therapies, where he oversaw businesses including brain therapies, pain therapies, specialty therapies, and spine products. Earlier in his career, Martha spent nearly two decades at GE Healthcare and GE Capital in business development, strategic marketing, sales management, and general management roles. He earned a finance degree from Pennsylvania State University, graduating with highest honors, and was captain of the university’s men’s hockey team. He also serves in leadership and board roles involving business, healthcare, education, and community organizations.
Notable achievements
- Led Medtronic’s $43 billion acquisition of Covidien in 2015 and its subsequent integration before becoming CEO.
- During the COVID-19 pandemic, authorized the open sourcing of Medtronic ventilator design information to help manufacturers increase supply.
- Oversaw the launch and expansion of newer growth platforms, including pulsed-field ablation, renal denervation, robotics, and neuromodulation products.
- Directed the 2025 plan to separate Medtronic’s Diabetes business into a standalone company as part of a broader portfolio simplification effort.
- Under his tenure, Medtronic reported fiscal 2025 revenue of approximately $33.5 billion and raised its dividend.
Problem areas / controversies
- The FDA issued a 2021 warning letter to Medtronic concerning manufacturing and quality-system issues involving MiniMed 600-series insulin pumps.
- Medtronic stopped selling its HeartWare HVAD heart pump in 2021 after FDA safety concerns involving neurological adverse events, mortality, and subsequent recalls.
- Analysts and investors have criticized Medtronic for uneven growth and for taking longer than expected to convert its product pipeline and acquisitions into stronger operating performance.
- The planned Diabetes separation reflects a strategic reset, but it also highlights the business’s weaker margins and the challenges of managing a broad portfolio.